Trial Profile
A Phase I/II, Open-Label, Dose-Escalation Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rasdegafusp-alfa (Primary) ; Poly ICLC; Resiquimod
- Indications Advanced breast cancer; Bladder cancer; Malignant melanoma; Myeloma; Non-small cell lung cancer; Ovarian cancer; Sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Celldex Therapeutics Inc
- 06 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Oct 2012 Positive results were presented at the Annual Meeting of the Society for Immunotherapy in October 2012, and were reported in a Celldex Therapeutics media release.
- 10 Aug 2012 Celldex expects to present results from the phase I portion of the trial in the fourth quarter of 2012.